Long-term potency preservation following brachytherapy for prostate cancer

Area of Science:

• Oncology
• Urology
• Radiation Oncology

Background:

• Erectile function preservation is a key concern for men undergoing prostate cancer treatment.
• Previous studies on potency preservation after brachytherapy have been limited by smaller patient cohorts and shorter follow-up periods.

Purpose of the Study:

• To assess the long-term rates of potency preservation in men treated with brachytherapy for prostate cancer.
• To identify significant factors influencing potency preservation, including age, use of androgen deprivation therapy (ADT), and external beam radiation therapy (EBRT).

Main Methods:

• A cohort of 1063 potent men with T1-T3 prostate cancer treated between 1990 and 2007 underwent brachytherapy (seed implantation alone or combined with EBRT).
• Androgen deprivation therapy (ADT) was administered to 49.1% of patients.
• Erectile function was assessed using the Mount Sinai Erectile Function Score (MSEFS), with potency defined as a score of ≥2.

Main Results:

• The 5- and 10-year actuarial potency preservation rates were 68.0% and 57.9%, respectively.
• Younger age (<60 years), higher pretreatment erectile function (MSEFS=3), and absence of ADT were associated with significantly higher potency rates.
• Combination therapy (EBRT and/or ADT) and older age (>70 years) were linked to decreased potency preservation.

Conclusions:

• Age at treatment, baseline erectile function, and the use of combined therapies (EBRT/ADT) are critical factors influencing post-brachytherapy erectile function.
• These findings provide valuable insights for patient counseling and treatment planning regarding sexual health outcomes.